Inventor
OH SANGKON
US31 patents
⚠️ This page may combine multiple inventors who share the name “OH SANGKON”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BAYLOR RES INSTITUTE
17 patentsUS10286058B2May 14, 2019
Vaccines against HPV and HPV-related diseases
BAYLOR RES INSTITUTE6 citations84
US12214034B2Feb 4, 2025
Vaccines against HPV and HPV-related diseases
BAYLOR RES INSTITUTE1 citations75
US12016915B2Jun 25, 2024
Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
BAYLOR RES INSTITUTE1 citations73
US11717567B2Aug 8, 2023
Vaccines against HPV and HPV-related diseases
BAYLOR RES INSTITUTE1 citations73
US11267895B2Mar 8, 2022
Nucleic acids encoding anti-CD40 antibodies
BAYLOR RES INSTITUTE2 citations73
US11173202B2Nov 16, 2021
Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
BAYLOR RES INSTITUTE1 citations73
US10683361B2Jun 16, 2020
Anti-CD40 antibodies
BAYLOR RES INSTITUTE2 citations73
US10279030B2May 7, 2019
Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
BAYLOR RES INSTITUTE1 citations73
US10087256B2Oct 2, 2018
Method of making an anti-CD40 antibody
BAYLOR RES INSTITUTE2 citations73
US11806390B2Nov 7, 2023
Fusion proteins comprising an anti-CD40 antibody and cancer antigens
BAYLOR RES INSTITUTE2 citations71
US10980869B2Apr 20, 2021
Fusion proteins comprising an anti-CD40 antibody and cancer antigens
BAYLOR RES INSTITUTE1 citations71
US12186379B2Jan 7, 2025
Dendritic cell ASGPR targeting immunotherapeutics for multiple sclerosis
BAYLOR RES INSTITUTE1 citations64
US10940195B2Mar 9, 2021
Vaccines against HPV and HPV-related diseases
BAYLOR RES INSTITUTE0 citations62
US11957734B2Apr 16, 2024
Methods and compositions for treating autoimmune and inflammatory conditions
BAYLOR RES INSTITUTE0 citations60
US10993990B2May 4, 2021
Methods and compositions for treating autoimmune and inflammatory conditions
BAYLOR RES INSTITUTE0 citations60
US10167339B2Jan 1, 2019
Antagonistic anti-OX40L antibodies and methods of their use
BAYLOR RES INSTITUTE1 citations57
US10570208B2Feb 25, 2020
Antagonistic anti-OX40L antibodies and methods of their use
BAYLOR RES INSTITUTE0 citations47
BANCHEREAU JACQUES F
5 patentsUS8728481B2May 20, 2014
Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
BANCHEREAU JACQUES F30 citations96
US8236934B2Aug 7, 2012
Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
BANCHEREAU JACQUES F36 citations96
US9562104B2Feb 7, 2017
Anti-CD40 antibodies
BANCHEREAU JACQUES F10 citations92
US9109011B2Aug 18, 2015
Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef
BANCHEREAU JACQUES F27 citations89
US8481314B2Jul 9, 2013
Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1)
BANCHEREAU JACQUES F8 citations84
BAYLOR RES INST
4 patentsUS9453074B2Sep 27, 2016
Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
BAYLOR RES INST31 citations98
US9339556B2May 17, 2016
Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized LDL receptor-1 (LOX-1)
BAYLOR RES INST8 citations84
US9567401B2Feb 14, 2017
Anti-CD40 antibodies
BAYLOR RES INST2 citations73
US9315580B2Apr 19, 2016
Vaccines directed to langerhans cells
BAYLOR RES INST5 citations73